c-Rel activation requires MALT1′s function as a protease, as MI-2, an irreversible direct enzymatic inhibitor of MALT1, was shown to inhibit c-Rel nuclear translocation in human lymphoma cell lines in vitro and in a xenograft mouse model [42]. The gene discussed is REL; the disease is lymphoma.